A nationwide recall affecting nearly 16,000 bottles of a prescription blood pressure medication has been listed by the U.S. Food and Drug Administration (FDA) after a manufacturing quality issue raised concerns about whether patients are receiving the intended amount of one of the drug’s active ingredients.
The recall involves 15,696 bottles of Amlodipine and Olmesartan Medoxomil Tablets (5 mg/40 mg), a combination medication commonly prescribed to help control high blood pressure. The affected product was distributed across the United States by Ascend Laboratories and packaged in 30-count prescription bottles.
According to the FDA’s enforcement report, the reason for the recall is “Failed Dissolution Specifications: Olmesartan Medoxomil content below specifications.” While the wording is technical, the issue essentially means the tablet may not release the expected amount of olmesartan once taken. As a result, some patients may not receive the full therapeutic benefit intended by their prescribed treatment.
The recall was initially launched on May 5, 2026, and on June 2, 2026, the FDA assigned it a Class II recall classification. Under FDA guidelines, a Class II recall applies when a product may cause temporary or medically reversible health consequences, while the likelihood of serious adverse health effects remains relatively low.
Why This Blood Pressure Drug Recall Matters
Unlike several high-profile blood pressure medication recalls in recent years that involved concerns about potentially cancer-causing impurities, this action is not related to contamination. Instead, regulators are focused on product performance and whether patients are receiving the proper dose needed to effectively manage hypertension.
Amlodipine and olmesartan are often prescribed together because they target high blood pressure through different mechanisms. Amlodipine helps relax and widen blood vessels, while olmesartan blocks substances that cause blood vessels to tighten. When both ingredients work as intended, they can help reduce blood pressure and lower the risk of complications associated with hypertension.
If the olmesartan component is released below expected levels, blood pressure may not be controlled as effectively as prescribed. While the FDA has not reported widespread adverse events linked to the recall, healthcare professionals generally stress the importance of maintaining consistent treatment for patients managing chronic cardiovascular conditions.
The recalled medication can be identified using the following details:
- Product: Amlodipine and Olmesartan Medoxomil Tablets
- Strength: 5 mg/40 mg
- Lot Number: 24123460
- Package Size: 30-count bottles
- Expiration Date: October 31, 2027
- Distribution: Nationwide throughout the United States
Patients who find a matching lot number on their prescription bottle should contact their pharmacist or healthcare provider for guidance. Medical experts generally advise against stopping blood pressure medication abruptly without professional advice, as doing so can lead to elevated blood pressure levels and increase the risk of cardiovascular complications.
The recall also highlights the importance of ongoing blood pressure monitoring. Many people with hypertension experience no obvious symptoms until complications develop, making regular monitoring and treatment adherence especially important. Public health experts emphasized these concerns during World Hypertension Day 2026, which focused on improving awareness of uncontrolled high blood pressure and encouraging early intervention.
Read More
Consumers looking for official recall information can review updates through the FDA’s recall and safety alerts database. Patients should also continue monitoring their blood pressure and consult a healthcare professional if they notice unexpected changes in readings or experience symptoms such as severe headaches, dizziness, chest pain, or shortness of breath.
Although the FDA considers the probability of serious health consequences to be remote, the recall serves as a reminder that medication quality standards are critical to effective treatment. For millions of Americans managing hypertension, receiving the correct dose every day remains a key part of protecting long-term heart and vascular health.
Make Swikblog your go-to source on Google for reliable updates, smart insights, and daily trends.
